CVE-2024-41668

cBioPortal Proxy Endpoint Vulnerabliity

Description

The cBioPortal for Cancer Genomics provides visualization, analysis, and download of large-scale cancer genomics data sets. When running a publicly exposed proxy endpoint without authentication, cBioPortal could allow someone to perform a Server Side Request Forgery (SSRF) attack. Logged in users could do the same on private instances. A fix has been released in version 6.0.12. As a workaround, one might be able to disable `/proxy` endpoint entirely via, for example, nginx.

Category

8.3
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.08%
Affected: cBioPortal cbioportal
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2024-41668?
CVE-2024-41668 has been scored as a high severity vulnerability.
How to fix CVE-2024-41668?
To fix CVE-2024-41668, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-41668 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-41668 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-41668?
CVE-2024-41668 affects cBioPortal cbioportal.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.